MA59341A1 - Rifamycin analogs and antibody-drug conjugates thereof - Google Patents

Rifamycin analogs and antibody-drug conjugates thereof

Info

Publication number
MA59341A1
MA59341A1 MA59341A MA59341A MA59341A1 MA 59341 A1 MA59341 A1 MA 59341A1 MA 59341 A MA59341 A MA 59341A MA 59341 A MA59341 A MA 59341A MA 59341 A1 MA59341 A1 MA 59341A1
Authority
MA
Morocco
Prior art keywords
antibody
drug conjugates
growth
infections
aureus
Prior art date
Application number
MA59341A
Other languages
French (fr)
Inventor
Thomas Nittoli
Seungyong Sean Choi
Mrinmoy Saha
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA59341A1 publication Critical patent/MA59341A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés analogues de rifamycine, des intermédiaires et des précurseurs de ceux-ci, et des compositions pharmaceutiques capables d'inhiber la croissance bactérienne (par exemple, la croissance de s. Aureus) et de traiter des infections bactériennes (par exemple, des infections par s. Aureus). L'invention concerne en outre des conjugués anticorps-médicament de composés analogues de rifamycine et d'anticorps, par exemple, des anticorps spécifiques contre des cibles associées à une maladie infectieuse comme le récepteur de glycoprotéine membranaire (msr1), des acides téichoïques de paroi (wta) ou une protéine a, et des procédés d'utilisation de ceux-ci pour inhiber la croissance bactérienne et traiter des infections bactériennes.Disclosed herein are rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (eg, growth of S. Aureus) and treating bacterial infections (eg. example, S. Aureus infections). The invention further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific against targets associated with infectious disease such as the membrane glycoprotein receptor (msr1), cell wall teichoic acids (wta) or a protein, and methods of using the same to inhibit bacterial growth and treat bacterial infections.

MA59341A 2018-12-21 2021-07-28 Rifamycin analogs and antibody-drug conjugates thereof MA59341A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783506P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
MA59341A1 true MA59341A1 (en) 2023-05-31

Family

ID=83598749

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53783A MA53783A1 (en) 2018-12-21 2019-12-20 Rifamycin analogs and antibody-drug conjugates thereof
MA59341A MA59341A1 (en) 2018-12-21 2021-07-28 Rifamycin analogs and antibody-drug conjugates thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA53783A MA53783A1 (en) 2018-12-21 2019-12-20 Rifamycin analogs and antibody-drug conjugates thereof

Country Status (1)

Country Link
MA (2) MA53783A1 (en)

Also Published As

Publication number Publication date
MA53783A1 (en) 2022-09-30

Similar Documents

Publication Publication Date Title
MA66057A1 (en) RIFAMYCIN ANALOGUES AND ANTIBODY-DRUG CONJUGATES THEREOF
MX2024005839A (en) Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof.
MA51530B1 (en) FUSED RING COMPOUNDS
MA38289A1 (en) Pharmaceutical composition with improved bioavailability
MA47079B1 (en) Amino-triazolopyidin compounds and their use to treat cancer
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
JP2012504650A (en) Methods for regulating negative chemotaxis of immune cells
MA67288A1 (en) Tubularysins and Tubularysin-Protein Conjugates
ES2171723T3 (en) 3,4-DIARIL-2-HYDROXI-2,5-DIHYDROFURANS AS COX-2 INHIBITORS PROPHARMS.
MX2025008092A (en) Inhibitors of kif18a and uses thereof
WO2019217890A8 (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
EA200701113A1 (en) Macrolides
WO2022106897A3 (en) Methods and composition for kras modifications
MX2023013683A (en) FUSED ISOXAZOLIL COMPOUNDS AS LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS.
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
MA59341A1 (en) Rifamycin analogs and antibody-drug conjugates thereof
PH12022551810A1 (en) Protein-antiviral compound conjugates
CA3156671A1 (en) NUTRITIONAL COMPOSITIONS FOR THE MANAGEMENT OF HYPONATREMIA
MA39926B1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2023014784A (en) Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents.
FR3081686B1 (en) FOOD COMPOSITION INCLUDING PHYCOCYANIN
CA3156457A1 (en) 1,8-NAPHTYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AN AUTOIMMUNE DISEASE
EA202191739A1 (en) ANALOGUES OF RIFAMYCIN AND ANTIBODY-DRUG CONJUGATES WITH THEM
GEP20257781B (en) Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide
BR112022018731A2 (en) USE OF A THIENOPIRIDONE DERIVATIVE IN THE TREATMENT OF ADRENOLEUCODYSTROPHY OR ADRENOMYELONEUROPATHY